Darae Ko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Darae Ko has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
- Emelia J. Benjamin
Boston University Chobanian & Avedisian School of Medicine
11 shared publications - Ludovic Trinquart
Tufts Clinical and Translational Sciences Institute, Tufts University, Boston, USA
7 shared publications - Honghuang Lin
Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA
6 shared publications - Jelena Kornej
Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study Framingham, MA United States
6 shared publications - Dae Hyun Kim
Frailty Research Center, Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife , Boston, Massachusetts
5 shared publications - Sarah Rosner Preis
Boston University and NHLBI’s Framingham Heart Study, Framingham, USA
5 shared publications
Latest Publications
- 23 October 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (2) , 589-592
Post‐Stroke Atrial Fibrillation Detection With Insertable Cardiac Monitors in Patients With Dementia and Frailty
- 23 October 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (2) , 589-592
Post‐Stroke Atrial Fibrillation Detection With Insertable Cardiac Monitors in Patients With Dementia and Frailty
- 17 October 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (1) , 265-268
Patterns of Oral Anticoagulant Use in Atrial Fibrillation Following Transition to Long‐Term Care
Patterns of oral anticoagulant use for atrial fibrillation following transition to long-term care.
- 17 October 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (1) , 265-268
Patterns of Oral Anticoagulant Use in Atrial Fibrillation Following Transition to Long‐Term Care
Patterns of oral anticoagulant use for atrial fibrillation following transition to long-term care.
- 17 September 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (2) , 252-260
Inotrope selection in mixed cardiogenic shock with sepsis: a comparative analysis between milrinone and dobutamine
Rationale: Despite increasing recognition of mixed cardiogenic shock—particularly in patients with concomitant sepsis—there remains limited guidance on optimal inotropic selection, and the comparative effectiveness of different inotropes in this population is unclear. Objective: To examine the association between inotrope selection and in-hospital outcomes, including all-cause mortality, among patients with cardiogenic shock and sepsis. Methods: Using the PINC AI enhanced-claims database (2016-2022), we identified patients with cardiogenic shock and sepsis using International Classification of Diseases, Tenth Revision codes (ICD-10) that were present on hospital admission and a pharmacy charge code for dobutamine or milrinone within 2 days of hospitalization. The primary outcome was all-cause hospital mortality. Secondary outcomes included inotrope duration, in-hospital length of stay, atrial arrhythmia, initiation of renal replacement therapy, use of mechanical circulatory support devices, and heart transplantation. We used greedy nearest neighbor matching on the propensity score (dobutamine vs milrinone) followed by g-computation to estimate effects of inotrope selection on outcomes. We examined heterogeneity of treatment effect in patients with renal disease, congestive heart failure, pulmonary circulatory diseases, and on epinephrine prior to inotrope initiation. Results: Out of 10 447 included patients, 74.4% received dobutamine and 25.6% received milrinone. Postmatching characteristics between the milrinone and dobutamine groups were similar (all standardized mean differences <0.1). The primary outcome all-cause mortality was similar between the postmatched milrinone and dobutamine groups (41.6% vs 42.7%; risk difference, -1.4% [95% CI, -3.7% to 1.5%]; P = .40). Patients initiated on milrinone (vs dobutamine) had longer inotrope durations (5.1 vs 3.5 days; mean difference, 1.7 [95% CI, 1.4-1.9] days; P < .001), longer in-hospital length of stay (10.0 vs 9.1 days; mean difference, 0.9 [95% CI, 0.4-1.3] days; P < .001), and more usage of anti-arrhythmic agents (56.0% vs 44.5%; mean difference, 11.5% [95% CI, 8.9%-14.1%]; P < .001). We did not observe any heterogeneity of treatment effect for all-cause mortality based on the preexisting conditions of interest. Conclusions: Using a large, multicenter cohort, we identified no differences in all-cause mortality between dobutamine and milrinone among patients with concurrent cardiogenic shock and sepsis overall. However, secondary outcomes favored dobutamine.
- 17 September 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (2) , 252-260
Inotrope selection in mixed cardiogenic shock with sepsis: a comparative analysis between milrinone and dobutamine
Rationale: Despite increasing recognition of mixed cardiogenic shock—particularly in patients with concomitant sepsis—there remains limited guidance on optimal inotropic selection, and the comparative effectiveness of different inotropes in this population is unclear. Objective: To examine the association between inotrope selection and in-hospital outcomes, including all-cause mortality, among patients with cardiogenic shock and sepsis. Methods: Using the PINC AI enhanced-claims database (2016-2022), we identified patients with cardiogenic shock and sepsis using International Classification of Diseases, Tenth Revision codes (ICD-10) that were present on hospital admission and a pharmacy charge code for dobutamine or milrinone within 2 days of hospitalization. The primary outcome was all-cause hospital mortality. Secondary outcomes included inotrope duration, in-hospital length of stay, atrial arrhythmia, initiation of renal replacement therapy, use of mechanical circulatory support devices, and heart transplantation. We used greedy nearest neighbor matching on the propensity score (dobutamine vs milrinone) followed by g-computation to estimate effects of inotrope selection on outcomes. We examined heterogeneity of treatment effect in patients with renal disease, congestive heart failure, pulmonary circulatory diseases, and on epinephrine prior to inotrope initiation. Results: Out of 10 447 included patients, 74.4% received dobutamine and 25.6% received milrinone. Postmatching characteristics between the milrinone and dobutamine groups were similar (all standardized mean differences <0.1). The primary outcome all-cause mortality was similar between the postmatched milrinone and dobutamine groups (41.6% vs 42.7%; risk difference, -1.4% [95% CI, -3.7% to 1.5%]; P = .40). Patients initiated on milrinone (vs dobutamine) had longer inotrope durations (5.1 vs 3.5 days; mean difference, 1.7 [95% CI, 1.4-1.9] days; P < .001), longer in-hospital length of stay (10.0 vs 9.1 days; mean difference, 0.9 [95% CI, 0.4-1.3] days; P < .001), and more usage of anti-arrhythmic agents (56.0% vs 44.5%; mean difference, 11.5% [95% CI, 8.9%-14.1%]; P < .001). We did not observe any heterogeneity of treatment effect for all-cause mortality based on the preexisting conditions of interest. Conclusions: Using a large, multicenter cohort, we identified no differences in all-cause mortality between dobutamine and milrinone among patients with concurrent cardiogenic shock and sepsis overall. However, secondary outcomes favored dobutamine.
- 27 August 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (9) , e011890
Clinical Outcomes of Switching From Warfarin to Apixaban or Rivaroxaban in Patients With Atrial Fibrillation: A Nationwide Multidatabase Study
BACKGROUND: The benefits of switching from warfarin to direct oral anticoagulants in atrial fibrillation remain unclear. METHODS: This retrospective study used the Medicare fee-for-service (2013–2020) and Optum Deidentified Clinformatics Data Mart databases (2013–2023). Among patients with atrial fibrillation who received warfarin for at least 180 days, we created 2 cohorts: (1) patients switching to apixaban versus continuing warfarin (the apixaban cohort) and (2) patients switching to rivaroxaban versus continuing warfarin (the rivaroxaban cohort). The index date was the switch date for switchers and a matched date based on warfarin duration for warfarin continuers. After 1:1 propensity score matching, we estimated the rate ratios (RR) for a composite of ischemic stroke, major bleeding, and death in each database and pooled the results using meta-analysis. Subgroup analyses by claims-based frailty and by follow-up time (first 60 days versus beyond 60 days) were performed. RESULTS: In the apixaban cohort (n=164 480; mean age, 80.5 years; 55.5% female; median follow-up, 354 days), switching to apixaban was associated with a lower rate of composite outcome (97.1 versus 104.9 per 1000 person-years; rate ratio, 0.92 [95% CI, 0.89–0.95]) compared with continuing warfarin. In the rivaroxaban cohort (n=96 030, mean age 79.7 years, 54.8% female, median follow-up 365 days), switching to rivaroxaban was associated with an increased rate of composite outcome (105.8 versus 99.3 per 1000 person-years; rate ratio, 1.08 [95% CI, 1.04–1.13]). No heterogeneity by frailty levels was observed. However, switching was associated with an initial risk increase within the first 60 days, followed by risk attenuation beyond 60 days, for both apixaban and rivaroxaban. CONCLUSIONS: In patients with atrial fibrillation on warfarin therapy, switching to apixaban may reduce the risk of ischemic stroke, major bleeding, and death, whereas switching to rivaroxaban may increase the risk. For both apixaban and rivaroxaban, switching may temporarily increase risk during the first 60 days.
- 27 August 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (9) , e011890
Clinical Outcomes of Switching From Warfarin to Apixaban or Rivaroxaban in Patients With Atrial Fibrillation: A Nationwide Multidatabase Study
BACKGROUND: The benefits of switching from warfarin to direct oral anticoagulants in atrial fibrillation remain unclear. METHODS: This retrospective study used the Medicare fee-for-service (2013–2020) and Optum Deidentified Clinformatics Data Mart databases (2013–2023). Among patients with atrial fibrillation who received warfarin for at least 180 days, we created 2 cohorts: (1) patients switching to apixaban versus continuing warfarin (the apixaban cohort) and (2) patients switching to rivaroxaban versus continuing warfarin (the rivaroxaban cohort). The index date was the switch date for switchers and a matched date based on warfarin duration for warfarin continuers. After 1:1 propensity score matching, we estimated the rate ratios (RR) for a composite of ischemic stroke, major bleeding, and death in each database and pooled the results using meta-analysis. Subgroup analyses by claims-based frailty and by follow-up time (first 60 days versus beyond 60 days) were performed. RESULTS: In the apixaban cohort (n=164 480; mean age, 80.5 years; 55.5% female; median follow-up, 354 days), switching to apixaban was associated with a lower rate of composite outcome (97.1 versus 104.9 per 1000 person-years; rate ratio, 0.92 [95% CI, 0.89–0.95]) compared with continuing warfarin. In the rivaroxaban cohort (n=96 030, mean age 79.7 years, 54.8% female, median follow-up 365 days), switching to rivaroxaban was associated with an increased rate of composite outcome (105.8 versus 99.3 per 1000 person-years; rate ratio, 1.08 [95% CI, 1.04–1.13]). No heterogeneity by frailty levels was observed. However, switching was associated with an initial risk increase within the first 60 days, followed by risk attenuation beyond 60 days, for both apixaban and rivaroxaban. CONCLUSIONS: In patients with atrial fibrillation on warfarin therapy, switching to apixaban may reduce the risk of ischemic stroke, major bleeding, and death, whereas switching to rivaroxaban may increase the risk. For both apixaban and rivaroxaban, switching may temporarily increase risk during the first 60 days.
- 11 September 2024
- Published by Springer Nature in Drugs & Aging
- Vol. 41 (9) , 763-773
Prospective Monitoring of New Drugs in Older Adults with and without Frailty: Near-Real-Time Assessment of Effectiveness and Safety of Oral Anticoagulants in Medicare Data
Background and Objective Prospective sequential analyses after a new drug approval allow proactive surveillance of new drugs. In the current study, we demonstrate feasibility of frailty-specific sequential analyses for dabigatran, rivaroxaban, and apixaban versus warfarin. Methods We partitioned Medicare data from 2011 to 2020 into datasets based on calendar year following the date of drug approval. Each calendar year of data was added sequentially for analysis. We used a new-user, active comparative design by comparing the initiators of dabigatran versus warfarin, rivaroxaban versus warfarin, and apixaban versus warfarin. Patients aged ≥ 65 years with atrial fibrillation without contraindication to the anticoagulants were included. Claims-based frailty index ≥ 0.25 was used to define frailty. The initiators of each direct oral anticoagulant were propensity-score matched to the initiators of warfarin within each frailty status. The effectiveness outcome was ischemic stroke or systemic thromboembolism, and the safety outcome was major bleeding. For each calendar year, we estimated hazard ratios (HRs) and 95% confidence intervals (CIs) from Cox proportional hazards models using all data available up to that year. Results As an example of the results, in the 2020 dataset, compared with warfarin, apixaban was associated with a reduced risk of ischemic stroke or systemic thromboembolism (frail: HR 0.73, 95% CI 0.63–0.85; non-frail: HR 0.65, 95% CI 0.59–0.72) and major bleeding (frail: HR 0.63, 95% CI 0.57–0.69; non-frail: HR 0.59, 95% CI 0.56–0.63) in both frail and non-frail patients. We found evidence for apixaban’s effectiveness and safety within 1–2 years after the drug approval in frail older patients. Conclusion Our frailty-specific sequential analyses can be applied to future near-real-time monitoring of newly approved drugs.
- 11 September 2024
- Published by Springer Nature in Drugs & Aging
- Vol. 41 (9) , 763-773
Prospective Monitoring of New Drugs in Older Adults with and without Frailty: Near-Real-Time Assessment of Effectiveness and Safety of Oral Anticoagulants in Medicare Data
Background and Objective Prospective sequential analyses after a new drug approval allow proactive surveillance of new drugs. In the current study, we demonstrate feasibility of frailty-specific sequential analyses for dabigatran, rivaroxaban, and apixaban versus warfarin. Methods We partitioned Medicare data from 2011 to 2020 into datasets based on calendar year following the date of drug approval. Each calendar year of data was added sequentially for analysis. We used a new-user, active comparative design by comparing the initiators of dabigatran versus warfarin, rivaroxaban versus warfarin, and apixaban versus warfarin. Patients aged ≥ 65 years with atrial fibrillation without contraindication to the anticoagulants were included. Claims-based frailty index ≥ 0.25 was used to define frailty. The initiators of each direct oral anticoagulant were propensity-score matched to the initiators of warfarin within each frailty status. The effectiveness outcome was ischemic stroke or systemic thromboembolism, and the safety outcome was major bleeding. For each calendar year, we estimated hazard ratios (HRs) and 95% confidence intervals (CIs) from Cox proportional hazards models using all data available up to that year. Results As an example of the results, in the 2020 dataset, compared with warfarin, apixaban was associated with a reduced risk of ischemic stroke or systemic thromboembolism (frail: HR 0.73, 95% CI 0.63–0.85; non-frail: HR 0.65, 95% CI 0.59–0.72) and major bleeding (frail: HR 0.63, 95% CI 0.57–0.69; non-frail: HR 0.59, 95% CI 0.56–0.63) in both frail and non-frail patients. We found evidence for apixaban’s effectiveness and safety within 1–2 years after the drug approval in frail older patients. Conclusion Our frailty-specific sequential analyses can be applied to future near-real-time monitoring of newly approved drugs.
- Open Access
- 6 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (15) , e034529
Frailty and Clinical Outcomes of Ticagrelor Versus Clopidogrel in Older Adults With Acute Myocardial Infarction
Background: Ticagrelor is recommended over clopidogrel in acute coronary syndrome based on the results of the PLATO (Study of Platelet Inhibition and Patient Outcomes) trial. We aimed to emulate PLATO in older adults with and without frailty and with acute coronary syndrome treated with percutaneous coronary intervention. Methods and Results: We created a new‐user cohort of Medicare fee‐for‐service beneficiaries aged ≥65 years hospitalized for acute coronary syndrome from 2014 to 2018 and initiated ticagrelor or clopidogrel following percutaneous coronary intervention. Frailty was defined using a validated claims‐based frailty index ≥0.25. Coprimary outcomes were major adverse cardiovascular events and major bleeding. Follow‐up began on the date of first outpatient prescription for ticagrelor or clopidogrel and ended on the earliest date for an outcome event, death, discontinuation of the index drug, or disenrollment from Medicare. The study included 42 843 older adults; 23% were frail. After propensity score matching, the rates of major adverse cardiovascular events per 100 person‐years comparing ticagrelor versus clopidogrel groups were 7.8 and 7.3 in the frail cohort (hazard ratio [HR], 1.07 [95% CI, 0.84–1.36]) and 3.7 and 4.2 in the nonfrail cohort (HR, 0.87 [95% CI, 0.75–1.02]). The corresponding rates of major bleeding were 4.3 and 3.8 in the frail cohort (HR, 1.12 95% CI, [0.80–1.56]) and 2.2 and 1.8 in the nonfrail cohort (HR, 1.22 [95% CI, 0.98–1.51]). Conclusions: There was a trend toward a modest reduction in risk of major adverse cardiovascular events and a trend toward a modest increase in risk of major bleeding with ticagrelor compared with clopidogrel in the nonfrail cohort. There was insufficient evidence for the benefit of ticagrelor in frail older adults.
- 6 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (15) , e034529
Open AccessFrailty and Clinical Outcomes of Ticagrelor Versus Clopidogrel in Older Adults With Acute Myocardial Infarction
Background: Ticagrelor is recommended over clopidogrel in acute coronary syndrome based on the results of the PLATO (Study of Platelet Inhibition and Patient Outcomes) trial. We aimed to emulate PLATO in older adults with and without frailty and with acute coronary syndrome treated with percutaneous coronary intervention. Methods and Results: We created a new‐user cohort of Medicare fee‐for‐service beneficiaries aged ≥65 years hospitalized for acute coronary syndrome from 2014 to 2018 and initiated ticagrelor or clopidogrel following percutaneous coronary intervention. Frailty was defined using a validated claims‐based frailty index ≥0.25. Coprimary outcomes were major adverse cardiovascular events and major bleeding. Follow‐up began on the date of first outpatient prescription for ticagrelor or clopidogrel and ended on the earliest date for an outcome event, death, discontinuation of the index drug, or disenrollment from Medicare. The study included 42 843 older adults; 23% were frail. After propensity score matching, the rates of major adverse cardiovascular events per 100 person‐years comparing ticagrelor versus clopidogrel groups were 7.8 and 7.3 in the frail cohort (hazard ratio [HR], 1.07 [95% CI, 0.84–1.36]) and 3.7 and 4.2 in the nonfrail cohort (HR, 0.87 [95% CI, 0.75–1.02]). The corresponding rates of major bleeding were 4.3 and 3.8 in the frail cohort (HR, 1.12 95% CI, [0.80–1.56]) and 2.2 and 1.8 in the nonfrail cohort (HR, 1.22 [95% CI, 0.98–1.51]). Conclusions: There was a trend toward a modest reduction in risk of major adverse cardiovascular events and a trend toward a modest increase in risk of major bleeding with ticagrelor compared with clopidogrel in the nonfrail cohort. There was insufficient evidence for the benefit of ticagrelor in frail older adults.
- 9 July 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (2) , e25-e26
Letter by Ko et al Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”
- 9 July 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (2) , e25-e26
Letter by Ko et al Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”
- Open Access
- 15 April 2024
- Published by MDPI AG in Geriatrics
- Vol. 9 (2) , 50
Assessment and Management of Atrial Fibrillation in Older Adults with Frailty
Atrial fibrillation (AF) is a major driver of morbidity and mortality among older adults with frailty. Moreover, frailty is highly prevalent in older adults with AF. Understanding and addressing the needs of frail older adults with AF is imperative to guide clinicians caring for older adults. In this review, we summarize current evidence to support the assessment and management of older adults with AF and frailty, incorporating numerous recent landmark trials and studies in the context of the 2023 US AF guideline.
- 15 April 2024
- Published by MDPI AG in Geriatrics
- Vol. 9 (2) , 50
Open AccessAssessment and Management of Atrial Fibrillation in Older Adults with Frailty
Atrial fibrillation (AF) is a major driver of morbidity and mortality among older adults with frailty. Moreover, frailty is highly prevalent in older adults with AF. Understanding and addressing the needs of frail older adults with AF is imperative to guide clinicians caring for older adults. In this review, we summarize current evidence to support the assessment and management of older adults with AF and frailty, incorporating numerous recent landmark trials and studies in the context of the 2023 US AF guideline.
- Open Access
- 2 April 2024
- Published by American Medical Association (AMA) in JAMA
- Vol. 331 (13) , 1089-1090
Use of Lecanemab for Patients With Cardiovascular Disease
This Viewpoint discusses lecanemab use and the risk of cerebral macrohemorrhage for patients with mild cognitive impairment or early dementia.
- 2 April 2024
- Published by American Medical Association (AMA) in JAMA
- Vol. 331 (13) , 1089-1090
Open AccessUse of Lecanemab for Patients With Cardiovascular Disease
This Viewpoint discusses lecanemab use and the risk of cerebral macrohemorrhage for patients with mild cognitive impairment or early dementia.
- Open Access
- 10 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-7
Incidence and prognostic significance of newly-diagnosed atrial fibrillation among older U.S. veterans hospitalized with COVID-19
Most prior studies on the prognostic significance of newly-diagnosed atrial fibrillation (AF) in COVID-19 did not differentiate newly-diagnosed AF from pre-existing AF. To determine the association between newly-diagnosed AF and in-hospital and 30-day mortality among regular users of Veterans Health Administration using data linked to Medicare. We identified Veterans aged ≥ 65 years who were hospitalized for ≥ 24 h with COVID-19 from 06/01/2020 to 1/31/2022 and had ≥ 2 primary care visits within 24 months prior to the index hospitalization. We performed multivariable logistic regression analyses to estimate adjusted risks, risk differences (RD), and odds ratios (OR) for the association between newly-diagnosed AF and the mortality outcomes adjusting for patient demographics, baseline comorbidities, and presence of acute organ dysfunction on admission. Of 23,299 patients in the study cohort, 5.3% had newly-diagnosed AF, and 29.2% had pre-existing AF. In newly-diagnosed AF adjusted in-hospital and 30-day mortality were 16.5% and 22.7%, respectively. Newly-diagnosed AF was associated with increased mortality compared to pre-existing AF (in-hospital: OR 2.02, 95% confidence interval [CI] 1.72–2.37; RD 7.58%, 95% CI 5.54–9.62) (30-day: OR 1.86; 95% CI 1.60–2.16; RD 9.04%, 95% CI 6.61–11.5) or no AF (in-hospital: OR 2.24, 95% CI 1.93–2.60; RD 8.40%, 95% CI 6.44–10.4) (30-day: 2.07, 95% CI 1.80–2.37; RD 10.2%, 95% CI 7.89–12.6). There was a smaller association between pre-existing AF and the mortality outcomes. Newly-diagnosed AF is an important prognostic marker for patients hospitalized with COVID-19. Whether prevention or treatment of AF improves clinical outcomes in these patients remains unknown.
- 10 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-7
Open AccessIncidence and prognostic significance of newly-diagnosed atrial fibrillation among older U.S. veterans hospitalized with COVID-19
Most prior studies on the prognostic significance of newly-diagnosed atrial fibrillation (AF) in COVID-19 did not differentiate newly-diagnosed AF from pre-existing AF. To determine the association between newly-diagnosed AF and in-hospital and 30-day mortality among regular users of Veterans Health Administration using data linked to Medicare. We identified Veterans aged ≥ 65 years who were hospitalized for ≥ 24 h with COVID-19 from 06/01/2020 to 1/31/2022 and had ≥ 2 primary care visits within 24 months prior to the index hospitalization. We performed multivariable logistic regression analyses to estimate adjusted risks, risk differences (RD), and odds ratios (OR) for the association between newly-diagnosed AF and the mortality outcomes adjusting for patient demographics, baseline comorbidities, and presence of acute organ dysfunction on admission. Of 23,299 patients in the study cohort, 5.3% had newly-diagnosed AF, and 29.2% had pre-existing AF. In newly-diagnosed AF adjusted in-hospital and 30-day mortality were 16.5% and 22.7%, respectively. Newly-diagnosed AF was associated with increased mortality compared to pre-existing AF (in-hospital: OR 2.02, 95% confidence interval [CI] 1.72–2.37; RD 7.58%, 95% CI 5.54–9.62) (30-day: OR 1.86; 95% CI 1.60–2.16; RD 9.04%, 95% CI 6.61–11.5) or no AF (in-hospital: OR 2.24, 95% CI 1.93–2.60; RD 8.40%, 95% CI 6.44–10.4) (30-day: 2.07, 95% CI 1.80–2.37; RD 10.2%, 95% CI 7.89–12.6). There was a smaller association between pre-existing AF and the mortality outcomes. Newly-diagnosed AF is an important prognostic marker for patients hospitalized with COVID-19. Whether prevention or treatment of AF improves clinical outcomes in these patients remains unknown.